Table 1.
Demographic and Clinical Characteristics of the COVID-19 Patients Included in the Study.
| Total | VTE Positive | VTE Negative | P-value | |
|---|---|---|---|---|
| Number of patients | 131 | 29 (22%) | 102 (78%) | |
| Age (years) | 62 ± 15 | 57 ± 13 | .124# | |
| Gender | .464# | |||
| Males | 97 (74%) | 23 (79%) | 74 (73%) | |
| Females | 34 (26%) | 6 (21%) | 28 (27%) | |
| Co-morbidities and risk factors for VTE | ||||
| Body mass index | 26.5 ± 3.6 | 26.7 ± 4.5 | .822# | |
| Obesity (BMI ≥30) | 29 (22%) | 8 (28%) | 21 (21%) | .423# |
| Diabetes mellitus | 56 (43.1%) | 15 (51.7%) | 41 (40.6%) | .286# |
| Hypertension | 47 (35.9%) | 12 (41.4%) | 35 (34.3%) | .484# |
| COPD/Asthma | 4 (3.1%) | 1 (3.4%) | 3 (2.9%) | 1.000# |
| CAD/IHD | 11 (8.4%) | 2 (6.9%) | 9 (8.8%) | 1.000# |
| Hypothyroidism | 10 (7.6%) | 1 (3.4%) | 9 (8.8%) | .457# |
| History of previous VTE | 3 (2.3%) | 1 (3.4%) | 2 (2.0%) | .531# |
| History of active malignancy | 2 (1.5%) | 1 (3.4%) | 1 (1.0%) | .395# |
| Trauma/surgery during the past 4 weeks | 4 (3.1%) | 1 (3.4%) | 3 (2.9%) | 1.000# |
| Indications for CTPA | ||||
| Hypoxia | 76 (58%) | 21 (72.4%) | 55 (53.9%) | .090# |
| Respiratory distress | 102 (77.9%) | 23 (79.3%) | 79 (77.5%) | 1.000# |
| Chest pain | 3 (2.3%) | 0 | 3 (2.9%) | 1.000# |
| Tachycardia | 10 (7.6%) | 2 (6.9%) | 8 (7.8%) | 1.000# |
| Elevated d-dimer | 29 (22.1%) | 12 (41.4%) | 17 (16.7%) | .010* |
| Clinical signs of DVT | 4 (3.1%) | 3 (10.3%) | 1 (1.0%) | .034* |
| Laboratory parameters | ||||
| D-dimer | 10 864 ± 11 580 | 378 ± 491 | .0005** | |
| CRP | 69.9 ± 80.1 | 59 ± 54 | .396# | |
| Ferritin | 784 ± 1073 | 532 ± 645 | .117# | |
| Neutrophil/lymphocytes ratio | 16.2 ± 14.9 | 6.3 ± 5.4 | .001** | |
| Clinical course | ||||
| No of hospital stay days | 10.8 ± 4.6 | 8.3 ± 3.9 | .004** | |
#No Significance at P > .05 and *Significance at P < .05 and **Highly Significance at P < .01.